On 8 November 2016, India delivered the following statement on Review under Paragraph 8 of the Decision on the Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health.
India’s Interventions at the TRIPS Council meeting (08-09 November 2016)
Agenda Item 7: Review under Paragraph 8 of the Decision on the Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health
On Wednesday, 9 November 2016, India delivered the following statement at the World Trade Organization’s (WTO) TRIPS Council’s discussions of the United Nations Secretary-General’s High Level Panel Report on Access to Medicines.
Agenda item 13: the United Nations Secretary-General’s High Level Panel Report on Access to Medicines
Statement by India.
Thank you Chairman.
At the outset, I would like to thank delegations of Brazil, China and South Africa who are also co-sponsors of this agenda item.
On 24 July 2015, 17 Members of the World Trade Organization (WTO) tabled a draft Ministerial decision (published by the WTO secretariat on 29 July 2015) on “Non-violation and situation complaints” for “consideration at the 10th Ministerial Conference of the WTO” (Source: IP/C/W/607). The 10th Ministerial Conference of the WTO will take place in Nairobi from 15 December 2015 to 18 December 2015. Continue Reading
This Wednesday 21 May 2014, Knowledge Ecology International (KEI), Civil Society Coalition, Medecins Sans Frontieres (MSF), Oxfam, Health Action International (HAI) and Treatment Action Group (TAG) will host a side event at the WHA on, “Innovation and Access to Medicines and Vaccines: Emerging Challenges and Opportunities for Middle-Income Countries.”
By resolution WHA 59.24, the WHO’s Intergovernmental Working Group on Public Health, Innovation, and Intellectual Property (IGWG) has the goal of producing a Global Strategy and Plan of Action that will implement the CIPIH report recommendations and “secure an enhanced and sustainable basis for needs-driven, essential health research and development relevant to diseases that disproportionately affect developing countries, proposing cle Continue Reading
His Excellency Mr. Samak Sundaravej Prime Minister Government House Nakornpratom Rd. Dusit, Bangkok Thailand 10300 His Excellency Mr. Chaiya Sasomsap Minister of Public Health Tiwanont Rd. Talad Kwan District Nontaburi Province 11000 Thailand March 4, 2008 Re: Thailand Compulsory Licenses… Continue Reading
Between November 2006 and January 2007, Thailand issued compulsory licenses for two AIDS drugs (efavirnz and the combination of lopinavir+ritonavir) and one antihypertension drug (clopidegrel). The pharmaceutical industry has vehemently objected to these compulsory licenses, and has sought the US… Continue Reading
Monday, 30 April 2007 “The sanctioning of countries for using legitimate and important flexibilities in the TRIPS agreement brings shame to all U.S. citizens who are increasingly seen in Thailand and elsewhere as bullies and hypocrites.” The following is the… Continue Reading
On Friday, March 16, KEI organized a briefing in the U.S. Capitol on Thailand’s recent compulsory licenses on three drugs; two for HIV/AIDS (Merck’s efavirenz (Stocrin) and Abbott’s lopinavir + ritonavir (Kaletra)) and one for heart disease (Sanofi’s clopidogrel (Plavix)). … Continue Reading
Original page: http://www.cptech.org/ip/wto/p6/eu12052005.pdf Letter from CPTech referenced available here: https://www.keionline.org/32641 MARKOS KYPRIANOU PETER MANDELSON Member of the European Commission … Continue Reading